09.03.2021 14:30:00

Simulations Plus to Present at Oppenheimer Healthcare Conference

Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, will be presenting at Oppenheimer’s 31st Annual Healthcare Conference on Tuesday, March 16, 2021. Mr. O’Connor’s presentation, which will be webcast live, will begin at 2:30 p.m. ET. In addition, Mr. O’Connor and chief financial officer Will Frederick will host one-on-one meetings throughout the day.

The Company’s slide presentation will be available on the Investors page of the Simulations Plus website following the presentation. For more information about the Oppenheimer Annual Healthcare Conference, or to register to attend, please visit the conference website.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our vision is to improve health through innovative solutions, and our mission is to create value for our customers by accelerating and reducing the costs of R&D through innovative science-based software and consulting solutions that optimize treatment options and improve patient lives. For more information, please visit our website at www.simulations-plus.com.

Analysen zu Simulations Plus IncShsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Simulations Plus IncShs 28,58 -1,04% Simulations Plus IncShs